

APPENDIX C

OMB No. 0910-0695

Expiration Date: 02-28-2021

Paperwork Reduction Act Statement

According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0910-0695 and the expiration date is 2/28/2021. The time required to complete this information collection is estimated to average 15 minutes per response, including the time for reviewing instructions and completing and reviewing the collection of information

Name: _____

Reducing the Burden of Drug Costs on Patients

Post-Session Evaluation

The aim of this module, created by the University of Chicago in collaboration with the FDA, was created to educate providers on generic prescribing. Please note that once you start the post-test you cannot go back to questions you already answered.

Your participation in this module is voluntary and you can exit at any time. Submission of this post-test is considered implied consent. Your identity and information will remain private to the extent permitted by law. If you have any questions, please contact the ACP/AANP Research Department by email at <email> or phone at <phone>.

This module will take approximately 15 minutes.

Which of the following is TRUE about generic OCPs?

- a) Most brand name OCPs are not available in a generic form.
- b) Patients prescribed generic OCPs are less likely to adhere to their medication regimen.
- c) Generic OCPs represent a substantial individual and systems cost saving opportunity.
- d) Generic OCPs are marketed more than the brand name.
- e) Generic OCPs do not require additional testing before being marketed to the public.

Which is NOT considered a barrier when prescribing generic OCPs?

- a) Attitude toward generics
- b) Multiple generic brands

- c) Lack of knowledge
- d) Lack of generic availability
- e) Lack of trusted sources

When generic drugs are therapeutically equivalent, it means, that the following are required to be the same:

- a) Active ingredient
- b) Inactive ingredient
- c) Dosage form
- d) All of the above
- e) A and c only

For each statement below, please mark your level of agreement:

		Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
1.	In general, generic drugs are as effective as their corresponding brand-name versions	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2.	In general, generic drugs are as safe as their corresponding brand-name versions	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3.	In general, generic drugs do not cause more adverse effects than their corresponding brand-name versions.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

		Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
1.	I found this module useful.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2.	As a result of this module, I have less distrust of generic OCPs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3.	As a result of this module, I will discuss generic OCPs with my patients.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4.	As a result of this module, I will prescribe generic OCPs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Any other feedback on this module?

Thank you!